Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party

Aim: Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung cancer (NSCLC), without accurate predictor for response and survival, but important toxicity. Our aims were to identify predictive (for response) and prognostic (for survival) biological signatures in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghmans, Thierry, Ameye, Lieveke, Lafitte, Jean-Jacques, Colinet, Benoît, Cortot, Alexis, CsToth, Ingrid, Holbrechts, Stéphane, Lecomte, Jacques, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Richez, Michel, Scherpereel, Arnaud, Tulippe, Christian, Willems, Luc, Dernies, Tiffany, Leclercq, Nathalie, Sculier, Jean-Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309174/
https://www.ncbi.nlm.nih.gov/pubmed/25674536
http://dx.doi.org/10.3389/fonc.2014.00386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309174/
https://www.ncbi.nlm.nih.gov/pubmed/25674536
http://dx.doi.org/10.3389/fonc.2014.00386

Ejemplares similares